Skip to main content
Clinical Trials/TCTR20220525004
TCTR20220525004
Recruiting
Phase 4

The study to identify risk of botulinum toxin treatment failure due to the antibody

Merz Healthcare (Thailand) Company Limited0 sites500 target enrollmentMay 25, 2022

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Healthy human volunteers, Patient with history of botulinum toxin treatment failure.
Sponsor
Merz Healthcare (Thailand) Company Limited
Enrollment
500
Status
Recruiting
Last Updated
last year